The Clinical Outcome and Prognostic Factors for Survival by Patients with COVID-19 in a Community Hospital

• Published in: JAPANESE JOURNAL OF HOSPITAL GENERAL MEDICINE Vol. 19; no. 2; pp. 74 - 81
• Main Authors: Tanaka, Yoshiteru, Ina, Kenji, Koga, Toshimitsu, Ota, Yoshihiro, Tamaki, Hirofumi, Nambu, Takayuki, Kindaichi, Akihiro, Morizane, Atsushi, Hisada, Atsushi, Kayukawa, Satoshi, Ito, Tetsuya, Tajima, Yui, Tanaka, Ayaka, Okada, Yuka
• Format: Journal Article
• Language: Japanese
• Published: JAPAN SOCIETY OF HOSPITAL GENERAL MEDICINE 31.03.2023
• ISSN: 2185-8136; 2758-7878
• DOI: 10.60227/jhgmwabun.19.2_74

Mortality from coronavirus disease 2019 (COVID-19) has decreased since the special approval of therapeutic agents and widespread implementation of vaccination. However, there are only a few reports on the impact of therapeutic agents and vaccination on the clinical outcomes of patients with COVID-19 in community hospitals. Therefore, we conducted a retrospective survey of 90 patients with COVID-19 (including 72 patients receiving dialysis) hospitalized in a single community hospital to analyze their clinical outcomes and prognostic factors. No differences in the frequency of dialysis, diabetes mellitus, malignancy, or smoking history were observed between the survival ( n = 79) and non-survival groups ( n = 11). The percentage of people aged over 75 years, steroid usage, and the levels of C-reactive protein, D-dimer, and interferon-λ3 were significantly higher in the non-survival group than in the survival group, whereas the body mass index was lower in the non-survival group. However, the rate of vaccination and treatment with remdesivir and/or therapeutic antibodies was significantly higher in the survival group. These results suggest that vaccination and treatment with remdesivir and/or neutralizing antibodies contributes to improvement of clinical outcome of patients with COVID-19.